Catching a stomach bug on Ozempic, Wegovy, or Zepbound raises one main concern: fluid loss. Stomach viruses cause sudden vomiting and watery diarrhea. Those symptoms also appear on GLP-1 labels as a trigger for dehydration and kidney injury.
The reviewed sources do not provide a clinical trial of norovirus illness in people taking semaglutide or tirzepatide. Instead, doctors combine the fluid-loss warnings on drug labels with public-health guidance on dehydration.
Knowing those label facts helps you spot dehydration early. It also shows why your prescriber guides any dose change when you are sick.
Why winter stomach bugs matter on a GLP-1
The CDC's norovirus outbreak overview notes that U.S. outbreaks happen all year. They are most common from November to April. People call norovirus the "stomach flu," though it is not influenza (see getting a flu shot on semaglutide).
As of October 17, 2026, the day this article was written, the CDC CaliciNet report updated October 9, 2026, logged 160 confirmed outbreaks. The table covers confirmed outbreaks submitted from September 1, 2025, through September 30, 2026. Those lab submissions do not count all U.S. cases or predict a harsh winter.
Why does a virus matter on semaglutide or tirzepatide? The Zepbound prescribing information (Revised: 8/2026), Ozempic label (Revised: 5/2026), and Wegovy label (Revised: 6/2026) all warn about kidney injury.
In postmarketing reports, vomiting or diarrhea sometimes led to acute kidney injury, "in some cases requiring hemodialysis" (machine blood filtering). Each label tells clinicians to "Monitor renal function in patients reporting adverse reactions that could lead to volume depletion" (low body fluid). A stomach virus can add to fluid loss during treatment with semaglutide or tirzepatide.
Stomach bug on Ozempic or a medication side effect?
Telling a stomach bug on Ozempic, Wegovy, or Mounjaro from a drug reaction is hard because symptoms overlap. The CDC's norovirus symptom guide lists vomiting, watery diarrhea, nausea, and stomach pain, sometimes with fever or body aches. GLP-1 medicines can cause those same gut symptoms, especially during dose increases.
On the Wegovy 2.4 mg label, 44% of adults (nearly half) had nausea, 30% had diarrhea, and 24% had vomiting. Placebo rates in those trials were 16%, 16%, and 6%.
Zepbound (5 mg to 15 mg) listed nausea in 25% to 29% and vomiting in 8% to 13%, versus 8% and 2% on placebo. Ozempic diabetes trials (0.5 mg and 1 mg) reported nausea in about 16% to 20% and vomiting in 5% to 9%.
Because those trials studied different groups, their rates cannot rank one drug against another. A 2022 pooled STEP 1–3 analysis in Diabetes, Obesity and Metabolism found semaglutide gut events clustered around dose steps. In that study, "the median durations of nausea, diarrhoea and vomiting were 8, 3 and 2 days, respectively" among participants.
By comparison, the CDC notes norovirus usually starts 12 to 48 hours after exposure and clears in 1 to 3 days. Sick household members point to a virus, while a new dose step points to the medicine. Both can also happen together (see how long GLP-1 nausea lasts).
Brand-label missed-dose rules when shot day lands mid-illness
If you are throwing up on Wegovy or have stomach flu on tirzepatide, your dose day may land during illness. Each brand label has its own missed-dose window, and Ozempic's rule does not apply to Wegovy or Zepbound.
| Branded product | Missed-dose window | Label notes |
|---|---|---|
| Zepbound injection | The label permits administration within 4 days (96 hours); beyond that window, it calls for omission of the missed dose and resumption on the scheduled day. | Changing the weekly day requires at least 3 days (72 hours) between doses (§2.3). |
| Ozempic injection | The label permits administration within 5 days; beyond that window, it calls for omission of the missed dose and resumption on the scheduled day. | Applies to the weekly diabetes injection (§2.1). |
| Wegovy injection | The label permits the missed injection if the next dose is more than 2 days away and calls for omission if it is less than 2 days away. | After 2 or more consecutive missed injections, the label requires lower-dose re-escalation; the prescriber sets the restart plan (§2.4). |
| Wegovy daily tablet | The label calls for omission of the missed tablet and the next dose the following day. | Weekly injection rules do not apply to the branded tablet (§2.4). |
For one missed Wegovy shot, the label compares "more than 2 days away" with "less than 2 days away" before the next dose. It does not assign the exact two-day mark, so a prescriber or pharmacist guides that boundary.
These windows only cover an accidentally missed dose, not whether to inject during active vomiting. For a compounded prescription, the prescriber and dispensing pharmacy set the schedule. Any schedule change goes through the prescribing clinician.
Sick-day rules for GLP-1 medications and diabetes
Published sick day rules for GLP-1 medications depend on why you take the drug and symptom severity. A 2025 clinical guidance paper in Clinical Diabetes notes that semaglutide and tirzepatide often continue during mild illness. However, it lists "Significant/persistent nausea, vomiting, or diarrheal illness" as a reason clinicians consider holding a dose.
A February 2025 Dorset County Hospital NHS leaflet advises pausing "GLP-1 analogues … semaglutide" if you cannot eat or drink normally. That UK sheet covers type 2 diabetes patients also taking an SGLT-2 inhibitor, not all weight-loss patients.
For diabetes patients, the American Diabetes Association's sick-day guide notes that illness hormones can raise blood sugar while poor intake complicates lows. Combining a GLP-1 with insulin or a sulfonylurea raises hypoglycemia (low blood sugar) risk. Still, the Zepbound and Ozempic labels note that low blood sugar can also occur without those drugs.
The ADA also warns about diabetic ketoacidosis (DKA), a dangerous acid buildup when insulin runs too low. DKA warning signs include vomiting, abdominal pain, fruity breath, trouble breathing, and confusion. The ADA states: "The following are warning signs of DKA. If you experience any of these, contact your doctor immediately" for care.
At home, the CDC's norovirus prevention page recommends washing hands with soap and water for at least 20 seconds. Because "Hand sanitizer does not work well against norovirus," the CDC notes sanitizer is only an addition to soap and water.
When to call a doctor and how prescribed care works
For mild fluid loss, the CDC notes that oral rehydration solutions help. People with heart or kidney fluid limits should ask a clinician first. The CDC's dehydration signs include "Decreased urination," "Dry mouth and throat," and "Feeling dizzy when standing up" (see whether semaglutide causes dizziness).
The CDC adds: "If you think you or someone you are caring for is severely dehydrated, call your doctor" for care. The Ozempic Medication Guide says to contact a provider "right away" if stomach problems are "severe or will not go away" during treatment. All three labels warn that "persistent or severe abdominal pain," sometimes spreading to the back, can signal acute pancreatitis (pancreas inflammation).
The Zepbound label directs that "If pancreatitis is suspected, discontinue ZEPBOUND and initiate appropriate management" right away. The Ozempic guide likewise tells patients to stop the medicine and call a provider immediately (see semaglutide and pancreatitis).
When calling a clinician, share your last dose date, any recent dose increase, and when symptoms started. Also note sick household contacts, whether fluids stay down, urination changes, and any glucose readings.
Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. The FDA's September 2025 compounding Q&A states that "Compounded drugs are not FDA-approved" by the agency. The FDA does not verify their safety, effectiveness, or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. Medication prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy, giving you a clinical team to reach during illness.
